JP4483545B2 - Artificial blood vessel and manufacturing method thereof - Google Patents

Artificial blood vessel and manufacturing method thereof Download PDF

Info

Publication number
JP4483545B2
JP4483545B2 JP2004335754A JP2004335754A JP4483545B2 JP 4483545 B2 JP4483545 B2 JP 4483545B2 JP 2004335754 A JP2004335754 A JP 2004335754A JP 2004335754 A JP2004335754 A JP 2004335754A JP 4483545 B2 JP4483545 B2 JP 4483545B2
Authority
JP
Japan
Prior art keywords
blood vessel
artificial blood
artificial
tissue
retaining member
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2004335754A
Other languages
Japanese (ja)
Other versions
JP2006141681A (en
Inventor
泰秀 中山
圭一 神田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SHINKAN KOGYO KK
Original Assignee
SHINKAN KOGYO KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SHINKAN KOGYO KK filed Critical SHINKAN KOGYO KK
Priority to JP2004335754A priority Critical patent/JP4483545B2/en
Publication of JP2006141681A publication Critical patent/JP2006141681A/en
Application granted granted Critical
Publication of JP4483545B2 publication Critical patent/JP4483545B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Landscapes

  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Description

本発明は、生体内へ人工物を埋入した際にこれを被覆するように形成される組織体よりなる人工血管に係り、特に血管との縫合が容易な人工血管及びその製造方法に関する。 The present invention relates to an artificial blood vessel composed of a tissue body formed so as to cover an artificial object when it is embedded in a living body, and more particularly to an artificial blood vessel that can be easily sutured with a blood vessel and a method for manufacturing the same .

従来、人工血管としては、ポリエステル樹脂やPTFE樹脂製のメッシュからなるチューブが古くから実用化されており、小口径化や開存率向上などを課題として研究が進められている。現在までに検討されている技術は、主に、抗血栓材料として実績のあるセグメント化ポリウレタンチューブを使用したもの、グラフト鎖などを利用してヘパリンなどの抗血栓物質を表面に固定した人工血管材料などがある。   Conventionally, as an artificial blood vessel, a tube made of a mesh made of polyester resin or PTFE resin has been put into practical use for a long time, and researches are being conducted on issues such as reducing the diameter and improving the patency rate. The technologies that have been studied so far mainly include the use of segmented polyurethane tubes that have a proven track record as antithrombotic materials, and artificial blood vessel materials in which antithrombotic substances such as heparin are immobilized on the surface using graft chains. and so on.

本出願人は、生体内へ人工物を埋入した際にこれを被覆するように形成される組織体よりなる人工血管を特開2004−261260号にて提案している。該組織体は繊維質を含有しているため、物理的強度に優れており、組織適合性と血液適合性に優れる。
特開2004−261260号
The present applicant has proposed an artificial blood vessel made of a tissue body formed so as to cover an artificial object when it is embedded in a living body in Japanese Patent Application Laid-Open No. 2004-261260. Since the tissue body contains fiber, it has excellent physical strength and excellent tissue compatibility and blood compatibility.
JP 2004-261260 A

上記特開2004−261260号に記載の、生体内へ埋入した人工物の周囲を被覆するように形成される組織体を利用した人工血管は、それ自身の保形性を有しておらず、平たく潰れた形状となり易い。そのため、この人工血管は、生体中の血管と縫合しにくい。 An artificial blood vessel using a tissue body formed so as to cover the periphery of an artificial object embedded in a living body described in JP-A-2004-261260 does not have its own shape-retaining property. It tends to be flat and crushed. Therefore, this artificial blood vessel is difficult to suture with a blood vessel in the living body.

一般に、針と糸とを用いた血管の縫合には術者の技量に頼るところが大きく、特に、口径が3mm以下の小口径血管を縫合する際には、顕微鏡下での不自由な環境下で極めて小さな針と細い糸とによる縫合が必要であり、術者には習熟した特別な技術が要求され、そのような技術の修得にはかなりの年月を要する。人工血管に保形性がないと、血管との縫合術の難度はさらに高いものとなる。   In general, the suture of a blood vessel using a needle and a thread largely depends on the skill of the operator. Especially when a small-diameter blood vessel having a caliber of 3 mm or less is sutured, it is necessary to use a non-free environment under a microscope. Suturing with very small needles and thin threads is necessary, and the operator requires special skills that are well-trained, and it takes a considerable amount of time to acquire such techniques. If the artificial blood vessel does not have shape retention, the difficulty of suturing with the blood vessel is further increased.

本発明は、組織適合性及び血液適合性に優れた生体内へ人工物を埋入した際にこれを被覆するように形成される組織体よりなり、しかも血管との縫合が極めて容易となるように改良された人工血管及びその製造方法を提供することを目的とする。 The present invention comprises a tissue body that is formed so as to cover an artificial object embedded in a living body excellent in tissue compatibility and blood compatibility, and can be sutured easily with a blood vessel. An object of the present invention is to provide an improved artificial blood vessel and a method for producing the same.

本発明の人工血管は、生体内へ埋入した人工物の周辺に形成される管状の組織体よりなる人工血管において、該人工血管の端部の内側に円環形の保形部材が設けられている人工血管であって、該保形部材は、連通性のある多孔性三次元網状構造の熱可塑性樹脂よりなり、該熱可塑性樹脂の空孔に該組織体が入り込み、該熱可塑性樹脂の空孔の少なくとも一部が該組織体で埋まっていることを特徴とするものである。 The artificial blood vessel of the present invention is an artificial blood vessel formed of a tubular tissue body formed around an artificial object implanted in a living body, and an annular shape-retaining member is provided inside the end portion of the artificial blood vessel. a that artificial blood vessels,-holding-shaped member is made of a thermoplastic resin of the porous three-dimensional network structure with a communicability, the organization enters the pores of the thermoplastic resin, the thermoplastic resin At least a part of the pores is filled with the tissue body .

この保形部材は、平均孔径100〜650μm、見掛け密度0.01〜0.5g/cmの、連通性のある多孔性三次元網状構造の熱可塑性樹脂よりなるものが好ましい。 The shape-retaining member is preferably made of a thermoplastic resin having a porous three-dimensional network structure having an average pore diameter of 100 to 650 μm and an apparent density of 0.01 to 0.5 g / cm 3 .

本発明の人工血管の製造方法は、生体内へ埋入した人工物の周辺に形成される管状の組織体よりなる人工血管を製造する方法において、該人工血管の端部の内側に円環形の保形部材が設けられている人工血管であって、該保形部材は、連通性のある多孔性三次元網状構造の熱可塑性樹脂よりなり、該熱可塑性樹脂の空孔に該組織体が入り込み、該熱可塑性樹脂の空孔の少なくとも一部が該組織体で埋まっている人工血管を製造する方法であって、前記熱可塑性樹脂よりなる保形部材を装着した人工物を生体(人体を除く)内に埋入し、該保形部材及び人工物の外面に組織体を付着させると共に、該熱可塑性樹脂の空孔の少なくとも一部を組織体で埋める第1工程と、該第1工程の後、該人工物を生体内から取り出す第2工程と、該保部材及び人工物の外面に付着した組織体から、該人工物のみを引き抜く第3工程と、を有することを特徴とするものである。 The method for producing an artificial blood vessel according to the present invention is a method for producing an artificial blood vessel comprising a tubular tissue body formed around an artificial object implanted in a living body, and has an annular shape inside the end of the artificial blood vessel. An artificial blood vessel provided with a shape-retaining member, wherein the shape-retaining member is made of a thermoplastic resin having a porous, three-dimensional network structure, and the tissue enters the pores of the thermoplastic resin. A method for producing an artificial blood vessel in which at least a part of pores of the thermoplastic resin is embedded in the tissue body , wherein an artificial object equipped with a shape-retaining member made of the thermoplastic resin is a living body (excluding a human body) ) were implanted into, along with adhering the tissue body to the outer surface of the-holding-shaped member and artifacts, a first step of filling at least a portion of the pores of the thermoplastic resin in the organization, the first step after, a second step of taking out the artifacts from the living body,-holding-shaped member及From the tissue body attached to the outer surface of the artefact, it is characterized in that it has a third step of pulling out only the artifacts, the.

本発明の人工血管は、生体内へ人工物を埋入した際にこれを被覆するように形成される組織体よりなるため、生体適合性及び血液適合性に優れる。この人工血管は、端部に保形部材が設けられているので、血管との縫合が極めて容易である。   Since the artificial blood vessel of the present invention is composed of a tissue body formed so as to cover an artificial object when it is embedded in a living body, it is excellent in biocompatibility and blood compatibility. Since this artificial blood vessel is provided with a shape-retaining member at its end, it is very easy to suture with the blood vessel.

なお、この保形部材が、平均孔径100〜650μm、見掛け密度0.01〜0.5g/cmの、連通性のある多孔性三次元網状構造を有する熱可塑性樹脂よりなる場合には、この多孔性三次元網状構造部の空孔部分へコラーゲンなどの細胞外マトリックスを深部まで均質に含浸させること容易となり、また、組織からの細胞の侵入や毛細血管の構築などに有利に働くこととなる。また、この保形部材自体を人工血管として使用した場合にも、人工血管内壁に血管内皮細胞を存在させることが可能であり、閉塞が起こりにくく、結果として小口径の人工血管を実現することが可能である。 In the case where the shape retaining member is made of a thermoplastic resin having a porous three-dimensional network structure having an average pore diameter of 100 to 650 μm and an apparent density of 0.01 to 0.5 g / cm 3 , It becomes easy to uniformly impregnate an extracellular matrix such as collagen into the pores of the porous three-dimensional network structure part to the deep part, and it will be advantageous for invasion of cells from the tissue and construction of capillaries. . In addition, even when this shape-retaining member itself is used as an artificial blood vessel, it is possible for vascular endothelial cells to be present on the inner wall of the artificial blood vessel, which makes it difficult to block, and as a result, a small-diameter artificial blood vessel can be realized. Is possible.

以下に本発明の人工血管の実施の形態を詳細に説明する。   Hereinafter, embodiments of the artificial blood vessel of the present invention will be described in detail.

図1は実施の形態に係る人工血管の製造工程を示す模式的な断面図である。   FIG. 1 is a schematic cross-sectional view showing a process for manufacturing an artificial blood vessel according to an embodiment.

人工血管を製造するには、(a),(b)図の通り、棒状の人工物(以下、マンドレルということがある。)1を用意すると共に、このマンドレル1の両端にスポンジ状の保形部材2を装着する。この保形部材2は短い円筒形であり、マンドレル1に外嵌される。   In order to manufacture an artificial blood vessel, a rod-shaped artificial object (hereinafter sometimes referred to as a mandrel) 1 is prepared as shown in FIGS. The member 2 is attached. The shape retaining member 2 has a short cylindrical shape and is fitted on the mandrel 1.

この保形部材2付きのマンドレル1を生体内に埋入すると、やがて(c)図の通り、マンドレル1及び保形部材2の外面に組織体3が付着する。なお、スポンジ状の保形部材2内にも組織体が入り込み、スポンジ状保形部材2の空孔の少なくとも一部が組織体で埋まる。   When the mandrel 1 with the shape-retaining member 2 is embedded in the living body, the tissue 3 is eventually attached to the outer surfaces of the mandrel 1 and the shape-retaining member 2 as shown in FIG. The tissue also enters the sponge-shaped shape retaining member 2, and at least a part of the pores of the sponge-shaped shape retaining member 2 is filled with the tissue.

そこで、この埋入物を生体から取り出し、マンドレル1を引き抜く。これにより、(d)図に示すように組織体よりなり、両端に保形部材2が設けられた人工血管4が得られる。   Therefore, the implant is taken out from the living body and the mandrel 1 is pulled out. Thereby, the artificial blood vessel 4 which consists of a structure | tissue as shown to (d) figure and in which the shape-retaining member 2 was provided in the both ends is obtained.

この人工血管4は、生体内へ人工物を埋入した際にこれを被覆するように形成される組織体よりなるため、生体適合性及び血液適合性に優れる。また、両端にスポンジ状の円筒状の保形部材2が設けられ、両端が筒形を保つため、血管と容易に縫合することができる。なお、自己の体内で組織体を成長させた人工血管は、図1(d)の状態のものを人工血管として用いることもできる。動物体内で組織体を成長させる場合には、脱細胞処理して人工血管とする。   Since the artificial blood vessel 4 is composed of a tissue body formed so as to cover the artificial object when it is embedded in the living body, it is excellent in biocompatibility and blood compatibility. Moreover, since the sponge-shaped cylindrical shape-retaining member 2 is provided at both ends and the both ends maintain a cylindrical shape, it can be easily sutured with a blood vessel. Note that the artificial blood vessel in which the tissue body is grown in its own body can be used as the artificial blood vessel in the state shown in FIG. When a tissue body is grown in an animal body, it is decellularized to obtain an artificial blood vessel.

なお、図1の(e),(f),(g),(h),(i)図はそれぞれ(a)〜(d)図のE−E線、F−F線、G−G線、H−H線、I−I線に沿う断面図である。   1 (e), (f), (g), (h), and (i) are respectively the EE line, the FF line, and the GG line in FIGS. It is sectional drawing which follows the HH line and the II line.

本発明の人工血管の製造方法について、さらに詳細に説明する。   The method for producing an artificial blood vessel of the present invention will be described in further detail.

この人工血管は、生体内へ埋入した人工物の周辺に形成される管状の組織体よりなる。ここでいう生体とはヒト、ヤギ、ウシ、イヌ、ウサギ、ラット、マウスなど動物界に分類される生物を意味する。   This artificial blood vessel is composed of a tubular tissue body formed around an artificial object implanted in a living body. The living body here means an organism classified into the animal kingdom such as human, goat, cow, dog, rabbit, rat, mouse.

人工物の埋入部位としては例えば、人工物を受け入れる容積をある程度有する腹腔内や、四肢部、臀部又は背部などの臓器に近くない部位の皮下が好ましい。また、埋入には低侵襲な方法で行うことと動物愛護の精神を尊厳し、十分な麻酔下で最小限の切開術で行うことが好ましい。   For example, the site where the artificial object is to be implanted is preferably the abdominal cavity having a certain volume for receiving the artificial object, or the subcutaneous part of the site that is not close to an organ such as the extremity, buttocks or back. In addition, it is preferable to perform the implantation by a minimally invasive method and with a dignified spirit of animal welfare and with a minimal incision under sufficient anesthesia.

埋入する人工物(マンドレル1)としては、埋入した際に変形することがない強度(硬度)を有しており、化学的安定性があり、滅菌などの負荷に耐性があり、生体を刺激する溶出物がない又は少ないことから、好ましくは、本発明においては、アクリル樹脂、オレフィン樹脂、スチレン樹脂、ポリエステル樹脂、ポリアミド樹脂、塩化ビニル樹脂、シリコン樹脂、フッ素樹脂、エポキシ樹脂、ガラス、チタン、プラチナ、及びSUSからなる群から選択される少なくとも1種を基材とし、該基材の表面にメチルメタクリレート、スチレン、2,2,2−トリフルオロエチレンメタクリレート、N,N−ジメチルアクリルアミド、メタクリル酸ナトリウム、及び(N,N−ジメチルアミノプロピルアクリルアミド)メチオダイドからなる群から選択されるモノマーの1種又は2種以上をグラフト重合したものを用いる。   The artificial object (mandrel 1) to be implanted has strength (hardness) that does not deform when implanted, has chemical stability, is resistant to loads such as sterilization, Preferably, in the present invention, acrylic resin, olefin resin, styrene resin, polyester resin, polyamide resin, vinyl chloride resin, silicon resin, fluororesin, epoxy resin, glass, titanium , Platinum and SUS as a base material, and methyl methacrylate, styrene, 2,2,2-trifluoroethylene methacrylate, N, N-dimethylacrylamide, methacrylic acid on the surface of the base material Group consisting of sodium acid and (N, N-dimethylaminopropylacrylamide) methiodide Using one or more kinds of monomers selected those graft polymerization.

これらのモノマーを基材の表面に導入することにより、基材の表面の性状が改質され、良好な組織体を形成することができるようになる。   By introducing these monomers into the surface of the base material, the properties of the surface of the base material are modified, and a good structure can be formed.

また、特にメチルメタクリレートを基材の表面にグラフト重合させた場合は、この表面を更に、ジチオカーボネートポリマーでコーティングしても良い。即ち、メチルメタクリレートをグラフト重合させたアクリル樹脂の表面は接触角が約70°の疎水性であるが、これを若干強く、接触角で約80°とすることで形成される組織体の性質を微妙に調整することが可能となる。   In particular, when methyl methacrylate is graft-polymerized on the surface of the substrate, this surface may be further coated with a dithiocarbonate polymer. That is, the surface of the acrylic resin grafted with methyl methacrylate is hydrophobic with a contact angle of about 70 °. However, the surface of the acrylic resin has a slightly strong contact angle of about 80 °. It becomes possible to make fine adjustments.

表面にグラフト重合させるモノマーの種類によって、得られる組織体の性質が変化するため、どのようなモノマーを導入したアクリル樹脂を使用するかは、人工血管を移植吻合する生体血管のコンプライアンスβ値を考慮して当業者によって適宜選択することができる。   Depending on the type of monomer that is graft-polymerized on the surface, the properties of the resulting tissue will change, so what kind of monomer is used for the acrylic resin that is used depends on the compliance β value of the biological blood vessel that grafts an artificial blood vessel Thus, it can be appropriately selected by those skilled in the art.

これらのモノマーの基材表面へのグラフト重合は、例えばアクリル樹脂基材の表面に光重合開始剤を側鎖に有するポリスチレン誘導体を薄く塗布し、前記グラフト導入するモノマーの溶液へ浸漬して光開始グラフト重合することにより行うことが可能である。   Graft polymerization of these monomers onto the substrate surface is, for example, a thin coating of a polystyrene derivative having a photopolymerization initiator in the side chain on the surface of an acrylic resin substrate, and photoinitiation by dipping in the monomer solution to be grafted. It can be carried out by graft polymerization.

また、メチルメタクリレートをグラフト重合させたアクリル樹脂の表面をジチオカーボネートポリマーでコーティングする方法としては、ジチオカーボネートポリマー溶液を噴霧する方法や、浸漬する方法等が挙げられる。   Examples of the method of coating the surface of the acrylic resin graft-polymerized with methyl methacrylate with a dithiocarbonate polymer include a method of spraying a dithiocarbonate polymer solution and a method of dipping.

グラフト率は、X線光電子分光法で元素分率を測定することにより求めることができ、例えばポリメチルメタクリレートをグラフト導入する場合にはO/C比で0.30〜0.50、特に0.40程度が、さらにこれをジチオカーボネートポリマーでコーティングする場合はN/C比で0.022〜0.032、特に0.027程度であり、S/C比で0.040〜0.060、特に0.054程度であることが好ましい。また、ポリスチレンをグラフト導入した場合はO/C比で0.01〜0.05、特に0.03程度、ポリ(2,2,2−トリフルオロエチレンメタクリレート)をグラフト導入した場合はO/C比で0.30〜0.40、特に0.35程度、F/C比で0.35〜0.55、特に0.43程度、ポリ(N,N−ジメチルアクリルアミド)をグラフト導入した場合はN/C比で0.10〜0.30、特に0.20程度、O/C比で0.10〜0.30、特に0.18程度、ポリメタクリル酸ナトリウムをグラフト導入した場合は、O/C比で0.40〜0.60、特に0.49程度、Na/C比で0.10〜0.30、特に0.16程度、ポリ(N,N−ジメチルアミノプロピルアクリルアミド)メチオダイドをグラフト導入した場合はN/C比で0.05〜0.25、特に0.14程度、O/C比で0.05〜0.20、特に0.13程度、N/I比で0.8〜1.5、特に1.2程度が好適であり、得られる組織体の物性を移植しようとする生体血管の物体に近づけるべく、これらモノマーの重合時間、モノマー濃度などをパラメターとして当業者によって適宜調整すれば良い。 The graft ratio can be determined by measuring the elemental fraction by X-ray photoelectron spectroscopy. For example, when grafting polymethylmethacrylate, the O / C ratio is 0.30 to 0.50, especially 0. For example, when it is further coated with a dithiocarbonate polymer, the N / C ratio is 0.022 to 0.032, particularly about 0.027, and the S / C ratio is 0.040 to 0.060, particularly It is preferably about 0.054. When polystyrene is grafted, the O / C ratio is 0.01 to 0.05, particularly about 0.03. When poly (2,2,2-trifluoroethylene methacrylate) is grafted, O / C When the graft introduction of poly (N, N-dimethylacrylamide) is 0.30 to 0.40, especially about 0.35, and the F / C ratio is 0.35 to 0.55, especially about 0.43 N / C ratio of 0.10 to 0.30, especially about 0.20, O / C ratio of 0.10 to 0.30, especially about 0.18, and when sodium polymethacrylate is grafted, O / C ratio of 0.40 to 0.60, especially about 0.49, Na / C ratio of about 0.10 to 0.30, especially about 0.16, poly (N, N-dimethylaminopropylacrylamide) methiodide N / C when graft is introduced 0.05 to 0.25, especially about 0.14, O / C ratio 0.05 to 0.20, especially about 0.13, N / I ratio 0.8 to 1.5, especially 1. About 2 is preferable, and the polymerization time and the monomer concentration of these monomers may be appropriately adjusted by those skilled in the art as parameters to bring the physical properties of the obtained tissue body closer to the body of a biological blood vessel to be transplanted.

また、本発明においては生体内へ埋入する人工物の表面には、増殖因子としての生理活性物質を表面被覆するなどして固定することが可能である。増殖因子を固定することで、組織体の形成を促進することが可能であり、これにより組織体の形成のための人工物の埋入期間を短縮することができる。また、形成される組織体に毛細血管を誘導することができ、脱細胞処理後の密度や柔軟性などの物性値を人工血管としてより好ましい値に調整することも可能となる。   Further, in the present invention, the surface of an artificial object to be implanted into a living body can be fixed by covering the surface with a physiologically active substance as a growth factor. By fixing the growth factor, it is possible to promote the formation of a tissue body, thereby shortening the period for embedding an artifact for the formation of the tissue body. In addition, capillaries can be induced in the tissue body to be formed, and physical properties such as density and flexibility after decellularization can be adjusted to values more preferable as artificial blood vessels.

このような生理活性物質としては、血管内皮増殖因子、インスリン様増殖因子、インスリン様増殖因子結合蛋白や繊維芽細胞増殖因子が使用可能であり、例えば、血管内皮増殖因子を使用すれば毛細血管の誘導と内皮化の促進が可能となり、繊維芽細胞増殖因子を固定すれば組織体の形成を促進して短期間の埋入で人工血管として有用な組織体を形成させることができる。また、インスリン様増殖因子又はインスリン様増殖因子結合蛋白を固定すれば組織体に筋繊維を誘導することができる。生理活性物質の固定量としてはいずれの生理活性物質も0.1〜1.0μg/cm、特に0.5μg/cm前後が好適であり、人工血管に要求される物性や形成させるまでの期間を考慮して、当業者によって適宜増減すれば良い。 As such a physiologically active substance, vascular endothelial growth factor, insulin-like growth factor, insulin-like growth factor binding protein and fibroblast growth factor can be used. Induction and endothelialization can be promoted. When fibroblast growth factor is fixed, formation of a tissue body is promoted, and a tissue body useful as an artificial blood vessel can be formed by short-term implantation. In addition, when an insulin-like growth factor or an insulin-like growth factor binding protein is fixed, muscle fibers can be induced in the tissue. Physiologically active substances either as a fixed amount of the physiologically active substances 0.1~1.0μg / cm 2, is suitable in particular 0.5 [mu] g / cm 2 before and after, to thereby physical properties and form required for the artificial blood vessel It may be appropriately increased or decreased by those skilled in the art in consideration of the period.

埋入する人工物(マンドレル1)の形状としては、直径0.3〜15.0mmの棒状部を有するものであれば良く、これにより、人工物の直径(外径)をほぼ内径とする管状の組織体が得られる。この人工物が分岐部を有する場合には、分岐部以降の枝部分の径を同一のものを使用したり小さくしたりすることも可能であり、これにより種々の枝状の組織体を得ることができる。   The shape of the artificial object to be embedded (mandrel 1) may be any shape as long as it has a rod-shaped portion having a diameter of 0.3 to 15.0 mm. The organization body is obtained. When this artificial object has a branched portion, it is possible to use the same or smaller diameters of the branch portions after the branched portion, thereby obtaining various branch-like structures. Can do.

保形部材2は、好ましくは、平均孔径100〜650μmで、見掛け密度が0.01〜0.5g/cmの、連通性の、即ち、連続気孔性の多孔性三次元網状構造の熱可塑性樹脂よりなる。 The shape-retaining member 2 is preferably a continuous, continuous, porous three-dimensional network thermoplastic having an average pore diameter of 100 to 650 μm and an apparent density of 0.01 to 0.5 g / cm 3 . Made of resin.

この熱可塑性樹脂からなる多孔性三次元網状構造の平均孔径は100〜650μmで、見掛け密度は0.01〜0.5g/cmであるが、好ましい平均孔径は100〜400μm、より好ましくは100〜300μmである。見掛け密度としては0.01〜0.5g/cm範囲内であれば、細胞生着性が良好で、優れた物理的強度を維持し、生体に近似した弾性特性が得られるが、好ましくは0.01〜0.3g/cm、より好ましくは0.01〜0.2g/cmである。 The average pore diameter of the porous three-dimensional network structure made of this thermoplastic resin is 100 to 650 μm and the apparent density is 0.01 to 0.5 g / cm 3 , but the preferable average pore diameter is 100 to 400 μm, more preferably 100 ˜300 μm. If the apparent density is in the range of 0.01 to 0.5 g / cm 3 , cell engraftment is good, excellent physical strength is maintained, and elastic properties approximate to a living body are obtained. 0.01 to 0.3 g / cm 3 , more preferably 0.01 to 0.2 g / cm 3 .

また、平均孔径の概念において、孔径の分布は単分散の方が好ましく、細胞の侵入に重要な孔径サイズである孔径150〜300μmの孔の寄与率が高いことが望ましい。孔径150〜300μmの孔の寄与率が10%以上、好ましくは20%以上、より好ましくは30%以上、更に好ましくは40%以上、特に好ましくは50%以上あると、細胞が侵入し易く、また、侵入した細胞が接着、成長しやすいため、人工血管としての用途に有効である。   In the concept of average pore size, monodispersion is preferable for the pore size distribution, and it is desirable that the contribution ratio of pores having a pore size of 150 to 300 μm, which is an important pore size for cell invasion, is high. When the contribution ratio of pores having a pore diameter of 150 to 300 μm is 10% or more, preferably 20% or more, more preferably 30% or more, still more preferably 40% or more, and particularly preferably 50% or more, cells easily invade, Since invading cells are easy to adhere and grow, it is effective for use as an artificial blood vessel.

なお、多孔性三次元網状構造の平均孔径における孔径150〜300μmの孔の寄与率とは、後述の実施例1における平均孔径の測定方法における、全孔の数に対する孔径150〜300μmの孔の数の割合を指す。   Note that the contribution ratio of pores having a pore diameter of 150 to 300 μm in the average pore diameter of the porous three-dimensional network structure is the number of pores having a pore diameter of 150 to 300 μm with respect to the total number of holes in the method for measuring the average pore diameter in Example 1 described later. Refers to the percentage of

このような平均孔径、見掛け密度及び孔径分布の多孔性三次元網状構造であれば、細胞が容易に空孔部分へ浸透し、多孔性構造層へ細胞が接着、成長しやすい。   With such a porous three-dimensional network structure having an average pore size, apparent density, and pore size distribution, cells can easily penetrate into the pores, and the cells can easily adhere to and grow in the porous structure layer.

保形部材2を構成する熱可塑性樹脂としては、セグメント化ポリウレタン樹脂が抗血栓性や物理特性などの点でも優れた人工血管を得ることができ、好ましい。 The thermoplastic resin constituting the shape retaining member 2, it is possible to obtain a segment polyurethane resin excellent artificial blood vessel in terms of antithrombotic and physical properties, preferable.

セグメント化ポリウレタン樹脂は、ポリオール、ジイソシアネート及び鎖延長剤の3成分から合成され、いわゆるハードセグメント部分とソフトセグメント部分を分子内に有するブロックポリマー構造によるエラストマー特性を有するため、このようなセグメント化ポリウレタン樹脂を使用した場合に得られるスキャホールド材及び人工血管は、弾性力学的に生体血管に近似なS−S曲線(低血圧領域では高いコンプライアンスで低弾性であり、高血圧領域では低血圧領域よりも低いコンプライアンスの高弾性である特性)を示す管状構造体に成形することも可能であり、抗血栓性や物理特性にも優れている。   The segmented polyurethane resin is synthesized from three components of a polyol, a diisocyanate and a chain extender, and has an elastomeric property due to a block polymer structure having a so-called hard segment portion and soft segment portion in the molecule. The scaffold material and the artificial blood vessel obtained by using the S-S curve that is elastodynamically approximate to a biological blood vessel (high compliance and low elasticity in the low blood pressure region, and lower than the low blood pressure region in the high blood pressure region) It is also possible to form into a tubular structure exhibiting high compliance compliance properties, and excellent antithrombogenicity and physical properties.

また、熱可塑性樹脂が加水分解性又は生分解性を有するものであれば、人工血管の生体移植後に徐々に分解、吸収され、最終的には生着した細胞を残したまま樹脂製の基材自体を生体から排除することも可能である。   Also, if the thermoplastic resin is hydrolyzable or biodegradable, it is gradually decomposed and absorbed after the transplantation of the artificial blood vessel, and finally the resin base material leaving the engrafted cells. It is also possible to exclude itself from the living body.

このような熱可塑性樹脂で構成される多孔性三次元網状構造部には、コラーゲンタイプI,コラーゲンタイプII,コラーゲンタイプIII,コラーゲンタイプIV,アテロ型コラーゲン,フィブロネクチン,ゼラチン,ヒアルロン酸,ヘパリン,ケラタン酸,コンドロイチン,コンドロイチン硫酸,コンドロイチン硫酸B,ヒドロキシエチルメタクリレートとジメチルアミノエチルメタクリレートの共重合体,ヒドロキシエチルメタクリレートとメタクリル酸の共重合体,アルギン酸,ポリアクリルアミド,ポリジメチルアクリルアミド及びポリビニルピロリドンからなる群から選択される1種又は2種以上が保持されていても良く、更には繊維芽細胞増殖因子,インターロイキン−1,腫瘍増殖因子β,上皮増殖因子及び二倍体繊維芽細胞増殖因子よりなる群から選ばれる1種又は2種以上のサイトカイン類が保持されていても良く、更に、胚性幹細胞、血管内皮細胞、中胚葉性細胞、平滑筋細胞、末梢血管細胞及び中皮細胞よりなる群から選ばれる1種又は2種以上の細胞が接着されていても良い。胚性幹細胞は分化されたものであっても良い。   Porous three-dimensional network structures composed of such thermoplastic resins include collagen type I, collagen type II, collagen type III, collagen type IV, atelocollagen, fibronectin, gelatin, hyaluronic acid, heparin, keratan Acid, chondroitin, chondroitin sulfate, chondroitin sulfate B, copolymer of hydroxyethyl methacrylate and dimethylaminoethyl methacrylate, copolymer of hydroxyethyl methacrylate and methacrylic acid, alginic acid, polyacrylamide, polydimethylacrylamide and polyvinylpyrrolidone One or more selected may be retained, and may be fibroblast growth factor, interleukin-1, tumor growth factor β, epidermal growth factor and diploid fibroblast growth factor. 1 type or 2 or more types of cytokines selected from the group which may be hold | maintained from embryonic stem cells, vascular endothelial cells, mesoderm cells, smooth muscle cells, peripheral vascular cells, and mesothelial cells One or two or more cells selected from the group may be adhered. Embryonic stem cells may be differentiated.

この多孔性三次元網状構造層を構築する熱可塑性樹脂からなる骨格自体にも微細な孔を設けてもよい。このような微細孔は、骨格表面を平滑な表面でなく複雑な凹凸のある表面とし、コラーゲンや細胞増殖因子などの保持にも有効であり、結果として細胞の生着性を上げることが可能である。ただし、この場合の微細孔は、本発明でいう多孔性三次元網状構造部の平均孔径の計算の概念に導入されるものではない。   Fine pores may be provided in the skeleton itself made of the thermoplastic resin for constructing the porous three-dimensional network structure layer. Such micropores make the skeletal surface not a smooth surface but a complex uneven surface, and are also effective in retaining collagen and cell growth factors, and as a result, it is possible to increase cell engraftment. is there. However, the micropores in this case are not introduced into the concept of calculating the average pore diameter of the porous three-dimensional network structure referred to in the present invention.

この保形部材2の肉厚(外径(半径)と内径(半径)との差)は0.5〜1.0mm程度が好ましい。   The thickness (the difference between the outer diameter (radius) and the inner diameter (radius)) of the shape retaining member 2 is preferably about 0.5 to 1.0 mm.

組織体が形成されたマンドレル1は、該マンドレル1が直線状であれば生体内から摘出した後に、そのまま組織体から抜去すれば管状の組織体が得られ、直線状の人工血管とすることができる。なお、生理含塩水中に浸漬した状態で、マンドレル1を容易に抜き出すことができる。   If the mandrel 1 in which the tissue body is formed is extracted from the living body if the mandrel 1 is linear, a tubular tissue body can be obtained by removing the mandrel 1 from the body as it is, and a straight artificial blood vessel can be obtained. it can. In addition, the mandrel 1 can be easily extracted in the state immersed in physiological salt water.

人工物が分岐部を有する場合には生体内から摘出後に人工物のみを一部切断したり、破砕又は溶解することにより組織体から容易に除去することができ、分岐部を有する管状の組織体が得られる。この分岐部を有する組織体を用いた人工血管は、本発明の最も好ましい例である。即ち、血管の分岐部位は、血流が血管壁へぶつかるように当たっている部位であり、動脈瘤が発生しやすいが、このような分岐型人工血管であれば、これをそのまま動脈瘤の治療に使用することができる。   When the artificial object has a branched portion, a tubular tissue body having a branched portion can be easily removed from the tissue body by partially cutting, crushing, or dissolving the artificial object after extraction from the living body. Is obtained. An artificial blood vessel using a tissue having a branch portion is the most preferable example of the present invention. That is, the blood vessel branch site is a site where the blood flow hits the blood vessel wall, and an aneurysm is likely to occur. If such a branch type artificial blood vessel is used, it is used as it is for the treatment of the aneurysm. can do.

このようにして得られた組織体よりなる人工血管は、自己の体内にて成育させたものである場合には、これをそのまま用いることができる。他の動物で生育した場合には、組織体を脱細胞処理する。脱細胞処理の方法としては、コラゲナーゼなどの酵素処理によって細胞外マトリックスを溶出させて洗浄する方法やアルコールなどの水溶性有機溶媒で洗浄する方法があるが,グルタアルデヒドやホルムアルデヒドなどのアルデヒド化合物及び/又はメタノール、エタノール、イソプロピルアルコール等の水溶性有機溶媒で処理する方法がある。具体的には、アルデヒド化合物を終濃度1〜3%程度となるように調整し、組織体の体積の約50倍量の固定液中へ組織体を2時間以上浸漬する方法が好ましい。これによってタンパク鎖のリジン残基などを架橋することで、組織体の構造を維持することが可能となる。   When the artificial blood vessel composed of the tissue body thus obtained is grown in its own body, it can be used as it is. When grown in other animals, the tissue is decellularized. Methods for decellularization include elution of extracellular matrix by enzyme treatment such as collagenase and washing with a water-soluble organic solvent such as alcohol, but aldehyde compounds such as glutaraldehyde and formaldehyde and / or Alternatively, there is a method of treating with a water-soluble organic solvent such as methanol, ethanol or isopropyl alcohol. Specifically, a method in which the aldehyde compound is adjusted so as to have a final concentration of about 1 to 3%, and the tissue body is immersed in a fixative having a volume of about 50 times the volume of the tissue body for 2 hours or more is preferable. As a result, the structure of the tissue can be maintained by crosslinking lysine residues and the like of the protein chain.

脱細胞処理の後の組織体は、更に凍結乾燥することにより、密度などを安定して制御することができる。脱細胞処理後に凍結乾燥せずに、アルコールなどの水溶性有機溶媒、燐酸緩衝生理食塩水、生理食塩水中で保存することも可能であるが、保存時の物性変化を抑制する意味でも凍結乾燥させることが好ましい。ここで乾燥方法としては、乾燥時の収縮現象において空孔の閉塞や繊維質の会合が起こる可能性があり、再現性良く人工血管として有用な物性を有する組織体を得られなくなる可能性があるため、凍結乾燥が好ましい。   The tissue body after the decellularization treatment can be stably controlled in density and the like by further freeze-drying. It can be stored in water-soluble organic solvents such as alcohol, phosphate buffered saline, and physiological saline without lyophilization after decellularization treatment, but it is also lyophilized to suppress changes in physical properties during storage. It is preferable. Here, as a drying method, there is a possibility that pores are closed and fiber association occurs in the shrinkage phenomenon at the time of drying, and there is a possibility that a tissue body having physical properties useful as an artificial blood vessel cannot be obtained with good reproducibility. Therefore, lyophilization is preferred.

本発明によれば、人工物の材質、導入するモノマーの種類やその導入量、表面に固定する生理活性物質の種類や固定量、埋入期間等を調整することによって、様々なコンプライアンスβ値を有する人工血管を形成することができる。従って、本発明においては、これらの条件を調整することにより、吻合する生体血管のコンプライアンスβ値に近いコンプライアンスβ値を有する人工血管を形成することが好ましい。例えば、ヒト冠状動脈であればコンプライアンスβ値は約40であるが、ポリメチルメタクリレート鎖を表面にグラフト導入したアクリル樹脂製の人工物を1ヶ月間埋入して得られる組織体を脱細胞処理して得られる人工血管のコンプライアンスβ値は約40となり、冠状動脈用の人工血管として有用である。   According to the present invention, various compliance β values can be obtained by adjusting the material of the artifact, the type and amount of the monomer to be introduced, the type and amount of the physiologically active substance immobilized on the surface, the implantation period, and the like. An artificial blood vessel can be formed. Therefore, in the present invention, it is preferable to form an artificial blood vessel having a compliance β value close to the compliance β value of the biological blood vessel to be anastomosed by adjusting these conditions. For example, in the case of a human coronary artery, the compliance β value is about 40, but a tissue body obtained by implanting an artificial product made of acrylic resin grafted with polymethyl methacrylate chain on the surface for one month is decellularized. The compliance β value of the obtained artificial blood vessel is about 40, which is useful as an artificial blood vessel for a coronary artery.

以下に実施例を挙げて本発明をより具体的に説明する。   Hereinafter, the present invention will be described more specifically with reference to examples.

実施例1
[マンドレルの製作]
外径2mm、長さ30mmのシリコン樹脂製の丸棒(生体組織を物理的に必要以上に刺激しないように、丸棒表面は鏡面仕上げで両末端は半球状の曲面仕上げとした。)に光重合性開始剤を側鎖に有するポリスチレン誘導体を塗布し、常法によって精製したメチルメタクリレート・ベンゼン溶液中に浸漬して、光開始グラフト重合を行い、ポリメチルメタクリレート鎖を表面にグラフト導入した。グラフト率としては、X線光電子分光法により、O/C比で0.4であることが確認された。この丸棒よりなるマンドレル1の両端に、内径2mm、外径4mm、長さ3mmの円筒形の保形部材を装着した。この保形部材2付きのマンドレル1を常法によりエチレンオキサイドガス滅菌した。
Example 1
[Mandrel production]
Light on a round bar made of silicon resin with an outer diameter of 2 mm and a length of 30 mm (the round bar surface is mirror-finished and both ends are hemispherically curved so as not to physically irritate living tissue more than necessary). A polystyrene derivative having a polymerizable initiator in the side chain was applied, immersed in a methyl methacrylate / benzene solution purified by a conventional method, photoinitiated graft polymerization was performed, and a polymethyl methacrylate chain was grafted onto the surface. The graft ratio was confirmed to be 0.4 in O / C ratio by X-ray photoelectron spectroscopy. Cylindrical shape-retaining members having an inner diameter of 2 mm, an outer diameter of 4 mm, and a length of 3 mm were attached to both ends of the mandrel 1 made of this round bar. The mandrel 1 with the shape retaining member 2 was sterilized with ethylene oxide gas by a conventional method.

なお、この保形部材は次のようにして製造したものである。   This shape-retaining member is manufactured as follows.

[保形部材の製造]
熱可塑性ポリウレタン樹脂(日本ミラクトラン社製,ミラクトランE980PNAT)をN−メチル−2−ピロリジノン(関東化学社製,ペプチド合成用試薬,NMP)にディゾルバー(約2,000rpm)を使用して室温下で溶解して5.0%溶液(重量/重量)を得た。このNMP溶液約1.0kgをプラネタリーミキサー(井上製作所製,2.0L仕込み,PLM−2型)に秤量して入れ、ポリウレタン樹脂と同重量相当のメチルセルロース(関東化学社製,試薬,25cpグレード)を40℃で20分間混合し、その後攪拌を継続したまま10分間、20mmHg(2.7kPa)まで減圧して脱泡し、ポリマードープを得た。
[Manufacture of shape-retaining members]
Dissolve a thermoplastic polyurethane resin (Nippon Miractran, Milactolan E980PNAT) in N-methyl-2-pyrrolidinone (Kanto Chemical Co., peptide synthesis reagent, NMP) at room temperature using a dissolver (about 2,000 rpm). A 5.0% solution (weight / weight) was obtained. About 1.0 kg of this NMP solution was weighed into a planetary mixer (Inoue Seisakusho, 2.0 L, PLM-2 type), and methyl cellulose equivalent to the weight of polyurethane resin (Kanto Chemical Co., Reagent, 25 cp grade) ) Was mixed at 40 ° C. for 20 minutes, and then defoamed under reduced pressure to 20 mmHg (2.7 kPa) for 10 minutes with continued stirring to obtain a polymer dope.

化学実験用濾紙(東洋濾紙社製,定性分析用,2番)で作成した内径4mmφ,外径6mmφ,長さ60mmの筒状の紙管と、SUS440製の直径2mmφの芯棒と、この芯棒を紙管の中心部分に固定できる医用ポリプロピレン樹脂製の円柱状密栓から構成させるチューブ成形治具中に、上記ポリマードープを23ゲージの針を使用して射出注入し、その後密栓した後、還流状態にあるメタノール中へ投入して72時間還流を継続して、紙管面から内部のNMP溶媒を抽出除去することによりポリウレタン樹脂を凝固させた。この際、メタノールは還流状態を維持したまま、随時新液と交換した。72時間後、チューブ成形治具を還流状態のメタノールから乾燥させることなく室温下のメタノール浴中に移し、浴内でチューブ成形治具から内容物を取り出し、日本薬局方精製水中で72時間洗浄することによりメチルセルロース、メタノール及び残留するNMPを抽出除去した。洗浄用の水は随時新液を供給した。これを室温下で24時間減圧(20mmHg(2.7kPa))乾燥させて、管状の多孔性三次元網状構造体を製造した。これを所定長さに切断して保形部材2とした。   A cylindrical paper tube with an inner diameter of 4 mmφ, an outer diameter of 6 mmφ, and a length of 60 mm made with a filter paper for chemical experiments (manufactured by Toyo Roshi Kaisha, No. 2), a core rod made of SUS440 with a diameter of 2 mmφ, and this core The polymer dope was injected and injected using a 23 gauge needle into a tube forming jig composed of a cylindrical seal plug made of medical polypropylene resin capable of fixing the rod to the center of the paper tube, and then sealed after being sealed. The polyurethane resin was coagulated by throwing it into methanol in a state and continuing to reflux for 72 hours to extract and remove the internal NMP solvent from the paper tube surface. At this time, methanol was replaced with a new solution as needed while maintaining the reflux state. After 72 hours, the tube forming jig is transferred from the refluxed methanol to a methanol bath at room temperature without drying, and the contents are taken out from the tube forming jig in the bath and washed in Japanese Pharmacopoeia purified water for 72 hours. As a result, methylcellulose, methanol and remaining NMP were extracted and removed. Water for washing was supplied with new solution as needed. This was dried under reduced pressure (20 mmHg (2.7 kPa)) at room temperature for 24 hours to produce a tubular porous three-dimensional network structure. This was cut into a predetermined length to obtain a shape retaining member 2.

得られた保形部材について、下記方法により平均孔径及び見掛け密度の測定を行った。なお、平均孔径と見掛け密度の測定において、試料の切断は両刃カミソリ(フェザー社製,ハイステンレス)を使用して室温下で行った。   About the obtained shape-retaining member, the average pore diameter and the apparent density were measured by the following method. In the measurement of the average pore diameter and the apparent density, the sample was cut at room temperature using a double-edged razor (manufactured by Feather, high stainless steel).

(1)平均孔径の測定
両刃カミソリで切断した試料の平面(切断面)を実体顕微鏡(キーエンス社製,VH−6300)にて撮影した写真を使用して、同一平面上の個々の孔を三次元網状構造の骨格から包囲された図形として画像処理(画像処理装置はニレコ社のLUZEX
APを使用し、画像取り込みCCDカメラはSONYのLE N50を使用した。)し、個々の図形の面積を測定した。これを真円面積とし、対応する円の直径を求め孔径とした。多孔体の骨格部分に穿孔した微細孔を無視して同一平面上の連通孔のみを測定した結果、平均孔径は169±55μmと計測された。同時に、孔径分布における孔径150〜300μmの寄与率は71.2%と計測され、細胞接着に有効なサイズの孔を主体とする多孔体であることが確認された。
(1) Measurement of average pore diameter Using a photograph taken with a stereomicroscope (VH-6300, manufactured by Keyence Corporation) of the plane (cut surface) of a sample cut with a double-blade razor, individual holes on the same plane are tertiary. Image processing as a figure surrounded by the skeleton of the original network structure (Image processing device is LUZEX of Nireco)
AP was used and the image capturing CCD camera was a Sony LE N50. ) And the area of each figure was measured. This was defined as the perfect circle area, and the diameter of the corresponding circle was determined and used as the hole diameter. As a result of ignoring the fine holes drilled in the skeleton portion of the porous body and measuring only the communicating holes on the same plane, the average pore diameter was measured to be 169 ± 55 μm. At the same time, the contribution ratio of the pore size of 150 to 300 μm in the pore size distribution was measured to be 71.2%, and it was confirmed that the porous body was mainly composed of pores having a size effective for cell adhesion.

(2)見掛け密度の測定
約10mm長さに両刃カミソリで切断した試料を投影機(Nikon,V−12)にて測定して得た寸法より体積を求め、その重量を体積で除した値から求めた結果、0.077±0.002g/cmと計算された。
(2) Measurement of apparent density Volume is obtained from the dimension obtained by measuring a sample cut with a double-blade razor to a length of about 10 mm with a projector (Nikon, V-12), and the value obtained by dividing the weight by the volume. As a result, it was calculated as 0.077 ± 0.002 g / cm 3 .

[埋入及び摘出]
通常手技によって局所麻酔、剃毛されたウサギ背部の表皮をイソジン消毒後に速やかに約30mm切開し、滅菌した丸棒を皮下組織の下へ埋入して縫合した。縫合部位はイソジンにて1日2回の消毒を行い、水は自由給水とし、飼料としてオリエンタル酵母社製ORC4を体重に応じて適量給仕した。
[Embedding and extraction]
The epidermis of the back of a rabbit that was locally anesthetized and shaved by a normal procedure was dissected immediately after disinfection with isodine, and a sterilized round bar was embedded under the subcutaneous tissue and sutured. The suture site was disinfected with isodine twice a day, water was freely supplied, and an appropriate amount of ORC4 manufactured by Oriental Yeast Co., Ltd. was fed as feed.

埋入期間中、縫合部において感染の所見は認められず、抗生物質は一切使用する必要がなかった。埋入から1ヶ月後に埋入時と同様の手順にて丸棒を摘出した。摘出したマンドレル1及び保形部材2は、全面が肉厚約100ミクロンの組織体で均質に被覆されていた。   During the implantation period, there was no evidence of infection in the sutured area, and no antibiotics were required. One month after the implantation, a round bar was extracted in the same manner as at the time of implantation. The extracted mandrel 1 and shape retaining member 2 were uniformly coated with a tissue having a thickness of about 100 microns.

電子顕微鏡観察の結果、組織体に不規則な部分は存在せず、肉厚方向に対して均質な多孔体であることが分かる。   As a result of observation with an electron microscope, it can be seen that there is no irregular portion in the tissue body, and the porous body is homogeneous in the thickness direction.

次に、このマンドレル1の埋入期間を1ヶ月から2、3、4ヶ月と延長したこと以外は同様にして組織体を生成させた。   Next, a tissue body was generated in the same manner except that the period of embedding the mandrel 1 was extended from 1 month to 2, 3, 4 months.

[耐内圧試験]
埋入期間が1ヶ月のものと4ヶ月のもので耐内圧試験を行うと、水の圧入によって内圧を200mmHg(26.6kPa)まで負荷しても破裂することなく、この時に外径は約10%まで伸長した。この圧力負荷を0〜200mmHgの間で徐々に上下変化させ、繰り返し圧力負荷に対する外径の変化を確認したが、履歴回数によらず外径変化は同じ挙動を示し、本発明の人工血管が、血管の拍動に追従できる柔軟性を有していることが確認された。
[Internal pressure resistance test]
When the internal pressure resistance test is performed with the embedding period of 1 month and 4 months, the inner diameter does not rupture even when the internal pressure is applied up to 200 mmHg (26.6 kPa) by water injection, and the outer diameter is about 10 at this time. %. The pressure load was gradually changed up and down between 0 to 200 mmHg, and the change in the outer diameter with respect to the repeated pressure load was confirmed, but the outer diameter change showed the same behavior regardless of the number of histories, and the artificial blood vessel of the present invention was It was confirmed that it has the flexibility to follow the pulsation of blood vessels.

この人工血管は、端部にスポンジ状の保形部材を有するため、血管との縫合が極めて容易であった。   Since this artificial blood vessel has a sponge-like shape-retaining member at the end, it was extremely easy to suture with the blood vessel.

本発明の人工血管の製造方法を示す模式的な断面図である。It is typical sectional drawing which shows the manufacturing method of the artificial blood vessel of this invention.

1 マンドレル
2 保形部材
3 組織体
4 人工血管
1 Mandrel 2 Shape-retaining member 3 Tissue 4 Artificial blood vessel

Claims (5)

生体内へ埋入した人工物の周辺に形成される管状の組織体よりなる人工血管において、該人工血管の端部の内側に円環形の保形部材が設けられている人工血管であって、
該保形部材は、連通性のある多孔性三次元網状構造の熱可塑性樹脂よりなり、
該熱可塑性樹脂の空孔に該組織体が入り込み、該熱可塑性樹脂の空孔の少なくとも一部が該組織体で埋まっていることを特徴とする人工血管。
In an artificial blood vessel made of a tubular tissue body formed around an artificial object embedded in a living body, an artificial blood vessel in which an annular shape-retaining member is provided inside an end portion of the artificial blood vessel,
The shape-retaining member is made of a thermoplastic resin having a porous three-dimensional network structure having communication,
An artificial blood vessel, wherein the tissue body enters a hole of the thermoplastic resin, and at least a part of the hole of the thermoplastic resin is filled with the tissue body.
請求項1において、前記熱可塑性樹脂は、セグメント化ポリウレタン樹脂であることを特徴とする人工血管。   2. The artificial blood vessel according to claim 1, wherein the thermoplastic resin is a segmented polyurethane resin. 請求項1又は2において、前記多孔性三次元網状構造の平均孔径が100〜650μmで、見掛け密度が0.01〜0.5g/cmであることを特徴とする人工血管。 3. The artificial blood vessel according to claim 1, wherein the porous three-dimensional network structure has an average pore diameter of 100 to 650 μm and an apparent density of 0.01 to 0.5 g / cm 3 . 請求項1ないし3のいずれか1項において、該組織体が脱細胞処理されていることを特徴とする人工血管。   The artificial blood vessel according to any one of claims 1 to 3, wherein the tissue body is decellularized. 生体内へ埋入した人工物の周辺に形成される管状の組織体よりなる人工血管を製造する方法において、
該人工血管の端部の内側に円環形の保形部材が設けられている人工血管であって、
該保形部材は、連通性のある多孔性三次元網状構造の熱可塑性樹脂よりなり、
該熱可塑性樹脂の空孔に該組織体が入り込み、該熱可塑性樹脂の空孔の少なくとも一部が該組織体で埋まっている人工血管を製造する方法であって、
前記熱可塑性樹脂よりなる保形部材を装着した人工物を生体(人体を除く)内に埋入し、該保形部材及び人工物の外面に組織体を付着させると共に、該熱可塑性樹脂の空孔の少なくとも一部を組織体で埋める第1工程と、
該第1工程の後、該人工物を生体内から取り出す第2工程と、
該保部材及び人工物の外面に付着した組織体から、該人工物のみを引き抜く第3工程と、
を有することを特徴とする人工血管の製造方法。
In a method for producing an artificial blood vessel composed of a tubular tissue body formed around an artificial object implanted in a living body,
An artificial blood vessel in which an annular shape-retaining member is provided inside the end of the artificial blood vessel,
The shape-retaining member is made of a thermoplastic resin having a porous three-dimensional network structure having communication,
A method for producing an artificial blood vessel in which the tissue body enters the pores of the thermoplastic resin, and at least a part of the pores of the thermoplastic resin is filled with the tissue body ,
An artificial object equipped with a shape-retaining member made of the thermoplastic resin is embedded in a living body (excluding a human body) , and a tissue body is attached to the outer surface of the shape-retaining member and the artificial object. A first step of filling at least a portion of the hole with a tissue;
After the first step, a second step of removing the artifact from the living body,
A third step of extracting only the artificial object from the shape- retaining member and the tissue attached to the outer surface of the artificial object;
A method for producing an artificial blood vessel, comprising:
JP2004335754A 2004-11-19 2004-11-19 Artificial blood vessel and manufacturing method thereof Active JP4483545B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2004335754A JP4483545B2 (en) 2004-11-19 2004-11-19 Artificial blood vessel and manufacturing method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004335754A JP4483545B2 (en) 2004-11-19 2004-11-19 Artificial blood vessel and manufacturing method thereof

Publications (2)

Publication Number Publication Date
JP2006141681A JP2006141681A (en) 2006-06-08
JP4483545B2 true JP4483545B2 (en) 2010-06-16

Family

ID=36622016

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004335754A Active JP4483545B2 (en) 2004-11-19 2004-11-19 Artificial blood vessel and manufacturing method thereof

Country Status (1)

Country Link
JP (1) JP4483545B2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2013016B1 (en) 2014-06-17 2016-07-05 Academisch Ziekenhuis Leiden In situ tissue engineering.

Also Published As

Publication number Publication date
JP2006141681A (en) 2006-06-08

Similar Documents

Publication Publication Date Title
Fornasari et al. Natural-based biomaterials for peripheral nerve injury repair
Kokai et al. Diffusion of soluble factors through degradable polymer nerve guides: Controlling manufacturing parameters
TWI264301B (en) Multi-channel bioresorbable nerve regeneration conduit and preparation method for the same
US20040122454A1 (en) Medical guide tubes
US20100221304A1 (en) Bionanocomposite Materials and Methods For Producing and Using the Same
CA2121040A1 (en) Prevascularized polymeric implants for organ transplantation
JP2006021060A (en) Surgical prostheses
JPS6182746A (en) Artificial blood vessel
US10933163B2 (en) In situ tissue engineering
US20080268017A1 (en) Method of producing tissue by placing a molding support within a body cavity
JP4168740B2 (en) Collagen artificial blood vessel
JP2007037764A (en) Prosthetic valve
EP0246638A2 (en) Biologically modified synthetic grafts
JP2010088625A (en) Prosthetic valve
JP5676115B2 (en) Artificial blood vessel with valve, columnar core substrate for artificial blood vessel with valve, and method for producing artificial blood vessel with valve
JP4735111B2 (en) Stent with artificial valve
Watanabe et al. Development of biotube vascular grafts incorporating cuffs for easy implantation
JP4483545B2 (en) Artificial blood vessel and manufacturing method thereof
JP2007068879A (en) Biological implant member and artificial tissue
JP2004261260A (en) Artificial blood vessel
JP2007143833A (en) In vivo implanting member, and artificial tissue
JP4815936B2 (en) Artificial blood vessel having an artificial valve, manufacturing method thereof, and artificial blood vessel manufacturing material
JP2003284767A (en) Scaffolding material for system engineering and artificial blood vessel
EP1905464B1 (en) Implant and method for its production
CN111700710B (en) Template for tissue engineering material and tissue engineering material

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071023

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080612

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080612

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20080801

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080725

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20080801

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20090615

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091124

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100210

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100302

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100315

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130402

Year of fee payment: 3

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140402

Year of fee payment: 4

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

S303 Written request for registration of pledge or change of pledge

Free format text: JAPANESE INTERMEDIATE CODE: R316303

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250